Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Delveinsight's Extensive Coverage of
ESMO 2024 Conference

Home
esmo conference 2024

Results from a Phase Ia/Ib Study of ESG401, a Novel Trop2 Antibody-Drug Conjugate, in Patients with Different Subtypes of Metastatic Breast Cancer

The Phase Ia/Ib study of ESG401, a novel Trop2 ADC, showed promising and durable efficacy in metastatic breast cancer across various subtypes, particularly in first-line TNBC.

Efficacy, safety, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic clear-cell renal cell carcinoma (ccRCC): Results from a multi-center multi-country Phase 1/2a expansion cohort

Preliminary of 23andMe’s novel anti-CD200R1 monoclonal antibody in Phase I/II data from ESMO 2024 indicate manageable safety and efficacy, suggesting it could fill a critical gap in the ccRCC treatment landscape.

Amivantamab-chemotherapy Combo Phase I/II OrigAMI-1 Study

OrigAMI-1: Phase Ib/II open-label study evaluating RYBREVANT (Amivantamab) with FOLFOX or FOLFIRI in metastatic colorectal cancer.

The Phase I/II OrigAMI-1 study revealed that the amivantamab-chemotherapy combination exhibited promising, lasting antitumor effects with an ORR of 49% and a manageable safety profile in anti-EGFR-naive RAS/RAF wild-type mCRC.

Encorafenib + FOLFIRI Phase III BREAKWATER Study

Updated BREAKWATER safety lead-in results: Encorafenib + Cetuximab (EC) with FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).

The Phase III BREAKWATER study demonstrated the Encorafenib + FOLFIRI regimen’s promising efficacy in improving ORR, PFS, and OS, addressing the unmet need for targeted first-line treatments in BRAF V600E-mutant mCRC patients treated with one or fewer prior therapies.

Updated results of Duravelo-1: BT8009 monotherapy in PADCEV-naïve metastatic urothelial carcinoma (mUC) patients.

BT8009, a Nectin-4 targeted BTC developed by Bicycle Therapeutics, shows promising efficacy and safety in metastatic urothelial carcinoma, with a 45% overall response rate and a well-tolerated safety profile.

Initial Findings from the Phase III EORTC-GUCG 1333/PEACE-III Trial: Comparing XTANDI Alone vs XTANDI with XOFIGO in Asymptomatic/Mildly Symptomatic Bone Metastatic mCRPC

Data from the Phase III PEACE-3 trial at ESMO 2024 showed that combining XTANDI with XOFIGO significantly improved rPFS (16.4 to 19.4 months) and OS (35.0 to 42.3 months) in patients with mCRPC and bone metastases.

Our Recent Articles

Targets / Technology

Indications

Case Studies

Conference Coverage For Competitive Intelligence Insights On Liquid Biopsy

Discover how a leading Diagnostic Company monitored the activities and data readouts of competitor liquid biopsy tests at the ESMO 2023

Conference Coverage In Various Oncology Conferences

Learn how a big pharma company leveraged conference coverage solutions to comprehensively covert AACR, ASCO, and ESMO by meticulous conference planning

Competitive Intelligence News Monitoring

Discover how CI news monitoring significantly impacts your business growth

KOL Profiling

Learn how the engagement with respected KOLs bolstered the client's reputation as a leader in the pharma industry.

Due Diligence

Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics.

Newsletter and Whitepapers

Cancer Treatment Through Novel Biomarkers

Despite the challenges in the discovery of biomarkers. The paradigm of oncology is bright, with many biomarker-specific therapies being in the pipeline. The development of many more targeted therapies is anticipated with the use of biomarkers in the coming years as a significant cancer driver. Through this whitepaper, DelveInsight is representing the use of biomarkers in overcoming the disadvantages of current treatment options and therefore, changing the face of cancer treatment.

At DelveInsight, we are dedicated to providing comprehensive solutions that accelerate our clients' business growth and improve the healthcare industry. Our reputation as a leading partner in the expansion of various healthcare sectors is built on our expert consulting services and strategic foresight.

With a team of experienced professionals, including seasoned consultants and key opinion leaders (KOLs), we are equipped to tackle any complex challenge.

Diverse Array Of Solutions

We specialize in providing customized solutions, carefully tailored to meet the specific needs of our clients.

In-Depth Analysis

Our team has deep expertise in the healthcare industry. We provide efficient, dynamic, and innovative insights, along with indication-specific reports and services.

Schedule Your Appointment

Access the most effective business solutions for the oncology industry by connecting with the premier consultancy and forecasting service provider.

Delivering value through our expansive service offerings

Considering the ever-changing nature of the oncology therapy field, it's crucial to establish a competitive advantage for your business as soon as possible. Our range of consulting services and market research resources positions us well to guide you through obstacles while maximizing your strengths and opportunities.

We provide valuable insights to enhance your competitive edge and develop successful growth strategies. Join us on a journey to uncover opportunities and avoid pitfalls, as we simplify the process of optimizing your return on investment through our expert guidance.